- Home
- PAVM vs VYNE Comparison
PAVM vs VYNE Comparison
Compare PAVM & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- VYNE
- Stock Information
- Founded
- PAVM 2014
- VYNE 2003
- Country
- PAVM United States
- VYNE United States
- Employees
- PAVM N/A
- VYNE N/A
- Industry
- PAVM Medical/Dental Instruments
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- VYNE Health Care
- Exchange
- PAVM Nasdaq
- VYNE Nasdaq
- Market Cap
- PAVM 9.4M
- VYNE 9.6M
- IPO Year
- PAVM 2016
- VYNE 2018
- Fundamental
- Price
- PAVM $0.43
- VYNE $0.35
- Analyst Decision
- PAVM Strong Buy
- VYNE Buy
- Analyst Count
- PAVM 1
- VYNE 2
- Target Price
- PAVM $20.00
- VYNE $8.00
- AVG Volume (30 Days)
- PAVM 738.1K
- VYNE 3.1M
- Earning Date
- PAVM 11-12-2025
- VYNE 11-10-2025
- Dividend Yield
- PAVM N/A
- VYNE N/A
- EPS Growth
- PAVM N/A
- VYNE N/A
- EPS
- PAVM 0.83
- VYNE N/A
- Revenue
- PAVM $1,020,000.00
- VYNE $476,000.00
- Revenue This Year
- PAVM N/A
- VYNE N/A
- Revenue Next Year
- PAVM $234.47
- VYNE N/A
- P/E Ratio
- PAVM $0.52
- VYNE N/A
- Revenue Growth
- PAVM N/A
- VYNE N/A
- 52 Week Low
- PAVM $0.30
- VYNE $0.28
- 52 Week High
- PAVM $1.25
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- PAVM 44.31
- VYNE 45.19
- Support Level
- PAVM $0.40
- VYNE $0.34
- Resistance Level
- PAVM $0.48
- VYNE $0.38
- Average True Range (ATR)
- PAVM 0.06
- VYNE 0.03
- MACD
- PAVM -0.01
- VYNE 0.00
- Stochastic Oscillator
- PAVM 19.15
- VYNE 16.76
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.